CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
To evaluate the safety and efficacy of BIC-19GG, BIC-2019, BIC-2219 in the treatment of relapsed/refractory B acute lymphoblastic leukemia/lymphoblastic lymphoma in children
B Lymphocytic Leukemia|B Lymphoblastic Lymphoma
DEVICE: CAR T cell injection
Overall survival and event-free survival, The prognosis of ALL children who underwent CAR-T cell therapy, 24 months post CAR-T cell infusion
Overall remission rate, The ORR of ALL children who underwent CAR-T cell therapy, One month post CAR-T cell infusion|Adverse events, Incidence of adverse events and its severity, 12 months post CAR-T cell infusion
To evaluate the safety and efficacy of BIC-19GG, BIC-2019, BIC-2219 in the treatment of relapsed/refractory B acute lymphoblastic leukemia/lymphoblastic lymphoma in children